A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS

Registry ID

A031102

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Last update

2016-06-01

Conditions

• GERM CELL TUMOUR

Related clinical trials

• A PHASE II TRIAL EVALUATING CHEMOTHERAPY FOLLOWED BY RESPONSE-BASED REDUCED RADIATION THERAPY FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM GERMINOMAS
• A PHASE 2 TRIAL OF CHEMOTHERAPY FOLLOWED BY RESPONSE-BASED WHOLE VENTRICULAR & SPINAL CANAL IRRADIATION (WVSCI) FOR PATIENTS WITH LOCALIZED NONGERMINOMATOUS CENTRAL NERVOUS SYSTEM GERM CELL TUMOR
• PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS
• A PHASE 3 STUDY OF ACTIVE SURVEILLANCE FOR LOW RISK AND A RANDOMIZED TRIAL OF CARBOPLATIN VS. CISPLATIN FOR STANDARD RISK PEDIATRIC AND ADULT PATIENTS WITH GERM CELL TUMOURS

View on source registry